UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients

Journal of clinical oncology, 2007-12, Vol.25 (35), p.5584-5590

2007

Volltextzugriff (PDF)

The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer

Journal of clinical oncology, 2008-03, Vol.26 (8), p.1216-1222

2008

Volltextzugriff (PDF)

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.478-484

1999

Volltextzugriff (PDF)

Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction

Journal of clinical oncology, 2009-12, Vol.27 (36), p.6117-6123

2009

Volltextzugriff (PDF)

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer

Clinical breast cancer, 2016-04, Vol.16 (2), p.87-94

2016

Volltextzugriff (PDF)

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Clinical cancer research, 2011-08, Vol.17 (15), p.5132-5139

2011

Volltextzugriff (PDF)

Tamoxifen−DNA Adducts Detected in the Endometrium of Women Treated with Tamoxifen

Chemical research in toxicology, 1999-07, Vol.12 (7), p.646-653

1999

Volltextzugriff (PDF)

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

The Lancet (British edition), 2024-01, Vol.403 (10422), p.171-182

2024

Volltextzugriff (PDF)

Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer

Clinical breast cancer, 2010-12, Vol.10 (6), p.440-444

2010

Volltextzugriff (PDF)

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

Clinical cancer research, 2011-05, Vol.17 (10), p.3490-3499

2011

Volltextzugriff (PDF)

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

Clinical breast cancer, 2014-06, Vol.14 (3), p.154-160

2014

Volltextzugriff (PDF)

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience

The oncologist (Dayton, Ohio), 2017-02, Vol.22 (2), p.139-143

2017

Volltextzugriff (PDF)

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.677-686

2017

Volltextzugriff (PDF)

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.CT330-CT330

2015

Volltextzugriff (PDF)

Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.607-607

2015

Volltextzugriff (PDF)

Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.PD5-3-PD5-3

2015

Volltextzugriff (PDF)

Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen

Carcinogenesis (New York), 2000-08, Vol.21 (8), p.1461-1467

2000

Volltextzugriff (PDF)

Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.633-633

2014

Volltextzugriff (PDF)

A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin―Cyclophosphamide (AC) Followed by Nanoparticle Albumin―Bound Paclitaxel in Early-Stage Breast Cancer

Clinical cancer research, 2011-05, Vol.17 (10), p.3398-3407

2011

Volltextzugriff (PDF)

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma

Journal of clinical oncology, 1994-11, Vol.12 (11), p.2296-2300

1994

Volltextzugriff (PDF)

A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.267

2011

Volltextzugriff (PDF)

A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.267

2011

Volltextzugriff (PDF)

Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

Breast cancer research and treatment, 2011-02, Vol.126 (1), p.267-267

2011

Volltextzugriff (PDF)

pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

Breast cancer research and treatment, 2009-06, Vol.115 (3), p.609-612

2009

Volltextzugriff (PDF)

Role of adjuvant therapy in surgically resected colorectal carcinoma

Gastroenterology (New York, N.Y. 1943), 1995-09, Vol.109 (3), p.984-993

1995

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(86)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(103)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(72)
Science & Technology
(72)
Humans
(68)
Female
(37)
Adult
(24)
Middle Aged
(24)
Oncology
(24)
Biological And Medical Sciences
(23)
Aged
(21)
Male
(20)
Medical Sciences
(20)
United States
(16)
Clinical Trials
(13)
Breast Neoplasms - Drug Therapy
(12)
Pharmacology. Drug Treatments
(11)
Antineoplastic Agents
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(10)
General & Internal Medicine
(10)
Patients
(10)
Dose-Response Relationship, Drug
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Randomized, Controlled Trial of Acupuncture for the Treatment of Hot Flashes in Breast Cancer Patients

The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer

Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer

Dose-Dense Adjuvant Doxorubicin and Cyclophosphamide Is Not Associated With Frequent Short-Term Changes in Left Ventricular Ejection Fraction

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Tamoxifen−DNA Adducts Detected in the Endometrium of Women Treated with Tamoxifen

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2‐Positive Early Stage Breast Cancer: A Single Center Experience

Cognitive function and discontinuation of adjuvant hormonal therapy in older breast cancer survivors: CALGB 369901 (Alliance)

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result

Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen

Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC)

A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin―Cyclophosphamide (AC) Followed by Nanoparticle Albumin―Bound Paclitaxel in Early-Stage Breast Cancer

Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma

A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

Role of adjuvant therapy in surgically resected colorectal carcinoma

Suchergebnisse filtern